Pfizer Aromasin Cleared For Early Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer's oncologic Aromasin (exemestane) received approval Oct. 5 for the adjuvant treatment of early breast cancer in patients crossing over from tamoxifen therapy
Pfizer's oncologic Aromasin (exemestane) received approval Oct. 5 for the adjuvant treatment of early breast cancer in patients crossing over from tamoxifen therapy. Aromasin's additional indication is for "adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer following two to three years of tamoxifen for a completion of five consecutive years of adjuvant hormonal therapy," Pfizer said. Pfizer's Intergroup Exemestane Study found a 31% reduced risk of cancer recurrence in patients switching to Aromasin tablets versus those remaining on tamoxifen. Aromasin was previously approved for treatment of advanced breast cancer in patients whose disease progressed following tamoxifen therapy. Novartis is studying Femara (letrozole) in patients crossing over from tamoxifen, with results expected in 2008. The firm has already submitted the breast cancer therapy for an early adjuvant claim (1 (Also see "Novartis Submits Femara For Early Adjuvant Treatment Of Breast Cancer" - Pink Sheet, 11 Jul, 2005.)). |